Case 6-2007: A 28-year-old man with a mass in the testis

New England Journal of Medicine

Volumn 356, Issue 8, 2007, Pages 842-849

  Kaufman, Donald S ^a,b   Saksena, Mansi A ^a,b   Young, Robert H ^a,b   Tabatabaei, Shahin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; ANTINEOPLASTIC AGENT; CISPLATIN; TUMOR MARKER;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; PATHOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TESTIS BIOPSY; TESTIS DISEASE; CANCER STAGING; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; ECHOGRAPHY; LYMPHADENECTOMY; NEOPLASM; TESTIS; TESTIS TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847095993     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc069037     Document Type: Article

References (23)

1. Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 2005;66:1066-71.
2. Prout GR Jr, Griffin PP. Testicular tumors: delay in diagnosis and influence on survival. Am Fam Physician 1984;29:205-9.
3. Bosl GJ, Vogelzang NJ, Goldman A, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981;2:970-3.
4. Ulbright TM, Amin MB, Young RH. Tumors of the testis, adnexa, spermatic cord, and scrotum. Atlas of tumor pathology. 3rd series. Fascicle 25. Washington, DC: Armed Forces Institute of Pathology, 1999.
5. Ulbright TM, Young RH. Seminoma with tubular, microcystic, and related patterns: a study of 28 cases of unusual morphologic variants that often cause confusion with yolk sac tumor. Am J Surg Pathol 2005;29:500-5.
6. Emerson RE, Ulbright TM. The use of immunohistochemistry in the differential diagnosis of tumors of the testis and paratestis. Semin Diagn Pathol 2005;22:33-50.
7. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
8. Testis. In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging manual. 6th ed. New York: Springer, 2002:317-22.
9. Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21:1505-12.
10. Divrik RT, Akdogan B, Ozen H, Zorlu F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors - is shift to risk adapted policy justified? J Urol 2006;176:1424-9.
11. Ernst DS, Brasher P, Venner PM, et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol 2005;12:2575-80.
12. Spermon JR, Roeleveld TA, van der Poel HG, et al. Comparision of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology 2002;59:923-9.
13. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23:2781-8.
14. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-32.
15. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981;95:288-92.
16. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
17. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibisz JJ, Scheiner E. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986;4:1684-9.
18. Meinardi MT, Gietema JA, van der Graaf WTA, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32.
19. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-23.
20. Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor. J Urol 2000;163:1785-7.
21. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005;23:9130-7.
22. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000;18:2169-78.
23. Steingart R. Mechanisms of late cardiovascular toxicity from cancer chemotherapy. J Clin Oncol 2005;23:9051-2.